MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: John H. Strickler, Yoshiaki Nakamura, Takayuki Yoshino, Daniel V.T. Catenacci, Yelena Y. Janjigian, Afsaneh Barzi, Tanios S. Bekaii-Saab, Heinz-Josef Lenz, Jeeyun Lee, Eric Van Cutsem, Hyun Cheol Chung, MARIA ALSINA, Salvatore Siena, Joal Garrido Mayor, Maria Corinna Palanca-Wessels, Wentao Feng, John Marshall
Institutions: Duke Medical Center, National Cancer Center Hospital East, University of Chicago Medical Center, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, Mayo Clinic, Mayo Clinic Hospital, USC Norris Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University, Universitair Ziekenhuis Leuven, KU Leuven, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Seagen (United States), Georgetown University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3124240471